Financial overview

BerGenBio financial report data and keyfigures. History for income statement, balance sheet and cash flow.

Pre
Pre

Description

BerGenBio ASA is a clinical-stage biopharmaceutical Company focused on developing novel medicines for aggressive diseases.  The company’s clinical asset, bemcentinib, targeting the receptor tyrosine kinase AXL, is currently in development in a Ph1b/2a study in 1L STK 11 mutated NSCLC and preclinical development for severe respiratory infections.

Biotechnology